{"filing":{"accession_number":"0001213900-26-078150","cik":"0001912966","ticker":"RGNT","company_name":"REGENTIS BIOMATERIALS LTD.","form":"6-K","filing_date":"2026-07-15","report_date":null,"primary_document":"ea0298098-6k_regentis.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1912966/000121390026078150/ea0298098-6k_regentis.htm"},"events":[{"id":18053,"run_id":16206,"accession_number":"0001213900-26-078150","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Regentis announced European Notified Body approval of a next-generation, solvent-free manufacturing process for GelrinC® that increases production yield by 400% and improves scalability ahead of European commercial launch. This is a material operational and regulatory milestone—the approval enables commercial manufacturing with substantially improved efficiency and cost structure—but does not fit the discrete event categories (not an earnings release, M\u0026A, impairment, litigation, or executive change). The disclosure is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's ability to commercialize its lead product profitably.","company_name":"REGENTIS BIOMATERIALS LTD.","ticker":"RGNT","filing_date":"2026-07-15","form":"6-K","submitted_at":null,"items":[{"id":16754,"accession_number":"0001213900-26-078150","item_number":"EX-99.1","item_title":"ea029809801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Regentis announced European Notified Body approval of a next-generation, solvent-free manufacturing process for GelrinC® that increases production yield by 400% and improves scalability ahead of European commercial launch. This is a material operational and regulatory milestone—the approval enables commercial manufacturing with substantially improved efficiency and cost structure—but does not fit the discrete event categories (not an earnings release, M\u0026A, impairment, litigation, or executive change). The disclosure is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's ability to commercialize its lead product profitably.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T13:15:41.394469+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":16754,"accession_number":"0001213900-26-078150","item_number":"EX-99.1","item_title":"ea029809801ex99-1.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Regentis announced European Notified Body approval of a next-generation, solvent-free manufacturing process for GelrinC® that increases production yield by 400% and improves scalability ahead of European commercial launch. This is a material operational and regulatory milestone—the approval enables commercial manufacturing with substantially improved efficiency and cost structure—but does not fit the discrete event categories (not an earnings release, M\u0026A, impairment, litigation, or executive change). The disclosure is clearly operational/strategic in nature and would affect a reasonable investor's assessment of the company's ability to commercialize its lead product profitably.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-07-15T13:15:41.394469+00:00","company_name":"REGENTIS BIOMATERIALS LTD.","ticker":"RGNT","filing_date":"2026-07-15"}]}